12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT ID: NCT00240435
Last Updated: 2013-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
491 participants
INTERVENTIONAL
2002-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Boehringer Ingelheim Investigational Site
Downey, California, United States
University of California - Los Angeles
Los Angeles, California, United States
Boehringer Ingelheim Investigational Site
Palo Alto, California, United States
Rocky Mountain Center for Clinical Research
Wheat Ridge, Colorado, United States
Boehringer Ingelheim Investigational Site
Bay Pines, Florida, United States
Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
Boehringer Ingelheim Investigational Site
Wheaton, Maryland, United States
Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
Boehringer Ingelheim Investigational Site
New Hyde Park, New York, United States
Boehringer Ingelheim Investigational Site
Elizabeth City, North Carolina, United States
Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
St. Boniface General Hospital
Winnipeg, Manitoba, Canada
Boehringer Ingelheim Investigational Site
Courtice, Ontario, Canada
St. Joseph's Hospital Cardiac Research
Hamilton, Ontario, Canada
Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Department of Respiratory Medicine
Toronto, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
SMBD--Jewish General Hospital
Montreal, Quebec, Canada
Centre de Recherche Clinique -CUSE
Sherbrooke, Quebec, Canada
Hopital Laval
Ste-Foy, Quebec, Canada
c/o Hemodynamics Offices
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
205.252
Identifier Type: -
Identifier Source: org_study_id